Moxonidine: A review

Journal of Human Hypertension

Volumn 11, Issue 10, 1997, Pages 629-635

  Morris, S T W ^a   Reid, J L ^b  

^a WESTERN INFIRMARY   (United Kingdom)

^b NONE

Author keywords

Hypertension; I1 imidazoline receptor agonist; Imidazoline; Moxonidine

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAZOLINE I1 RECEPTOR; MOXONIDINE; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM; CHEMICAL STRUCTURE; CLINICAL TRIAL; DROWSINESS; DRUG EFFICACY; EDEMA; HEART FAILURE; HUMAN; HYPERTENSION; META ANALYSIS; NAUSEA; REVIEW; SLEEP DISORDER; SYNCOPE; UNSTABLE ANGINA PECTORIS; VERTIGO; XEROSTOMIA;

EID: 0030780747     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000518     Document Type: Review

References (58)

1. Armah BI, Hofferber E, Stenzel W. General pharmacology of the novel centrally-acting antihypertensive agent moxonidine. Drug Res 1988; 38: 1426-1434.
2. 1-Imidazoline receptor agonist. J Cardiovasc Pharmacol 1996; 27 (Suppl 3): S26-S37.
3. 1-Imidazoline receptors in the rostral ventrolateral medulla. J Cardiovasc Pharmacol 1994; 24 (Suppl 1): S1-S8.
4. Reis DJ, Morrison S, Ruggiero DA. The C1 area of the brainstem in tonic and reflex control of blood pressure: state of the art lecture. Hypertension 1988; 11 (Suppl 1): 8-13.
5. Reis DJ. Neurons and receptors in the rostroventrolateral medulla mediating the anti-hypertensive actions of drugs acting at imidazoline receptors. J Cardiovasc Pharmacol 1996; 27 (Suppl 3): S11-S18.
6. 1-imidazoline agonist moxonidine administered into the rostral ventrolateral medulla. J Cardiovasc Pharmacol 1992; 20 (Suppl 4): S11-S15.
7. Bousquet P, Feldman J, Schwartz J. Central cardiovascular effects of a adrenergic drugs: differences between catecholamines and imidazolines. J Pharm Exp Ther 1984; 230: 230-236.
8. 2 adrenoceptors: classification, localization, mechanisms and targets for drugs. J Med Chem 1982; 25: 1389-1401.
9. 2 adrenergic blocker. Am J Med Sci 1990; 299: 73-76.
10. 2 adrenoceptors in the ventrolateral medulla. Eur J Pharmacol 1987; 134: 1-13.
11. Ernsberger PR, Giuliano R, Willette RN, Reiss DJ. Role of imidazoline receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharmacol Exp Ther 1990; 253: 408-418.
12. De Vos H et al. Imidazoline receptors, non-adrenergic idazoxan binding sites and alpha 2-adrenoceptors in the human central nervous system. Neuroscience 1994; 59: 589-598.
13. Regunathan S, Meeley MP, Reis DJ. Expression of non-adrenergic imidazoline sites in chromaffin cells and mitochondrial membranes of bovine adrenal medulla. Biochem Pharmacol 1993; 45: 1667-1675.
14. Zonnenchein R, Diamant S, Atlas D. Imidazoline receptors in rat liver cells - a novel receptor or a sub-type of alpha 2-adrenoceptors? Eur J Pharmacol 1990; 190: 203-215.
15. 3H)idazoxan binding at non-alpha 2-adrenoceptors in rabbit adipocyte membranes. Eur J Pharmacol 1989; 159: 199-203.
16. 3H)idazoxan in the smooth muscle of rabbit urethra. Eur J Pharmacol 1988; 154: 209-212.
17. 2 sites. Br J Pharmacol 1994; 112(4): 1065-1070.
18. Michel MC, Ernsberger P. Keeping an eye on the I site: imidazoline-preferring receptors. Trends Pharmacol Sci 1992; 13: 369-370.
19. Bousquet P. Imidazoline receptors: from basic concepts to recent developments. J Cardiovasc Pharmacol 1995; 26 (Suppl 2): S1-S6.
20. Li G et al. Agmatine: an endogenous clonidine-displacing substance in the brain. Science 1994; 263: 966-969.
21. 1-Imidazoline receptors. J Cardiovasc Pharmacol 1992; 20: S1-S10.
22. Mitrovic V, Patyna W, Hüting J, Schlepper W. Haemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991; 5: 967-972.
23. Hüting J, Mitrovic V, Bahavar H, Schlepper M. Vergleich der Wirkungen von Moxonidin und Nifedipin die linskventriculäre Funktion bei Monotherapie der essentiellen Hypertonie. Herz Kreislauf 1992; 24: 132-136.
24. Klepzig H Jr et al. Akuter und chronischer Einfluss von Moxonidin auf Blutdruck und linskventriculäre Funktion in Ruhe und unter Belastung. In: Hayduk K. Stumpe KO (eds). Ein neues Therapieprinzip zur Behandlung der Hypertonie. Schattauer: Stuttgart. 1992, pp 23-30.
25. Kirch W, Hutt H-J, Plänitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration to hypertensive patients. J Clin Pharmacol 1990; 30: 1088-1095.
26. 1 imidazoline receptor agonist, moxonidine, on gastric secretion and gastric mucosal injury in rats. Br J Pharm 1995; 114(4): 51-754.
27. Lepran I, Papp JG. Effect of moxonidine on arrythmias induced by coronary artery occlusion and reperfusion. J Cardiovasc Pharmacol 1994; 24 (Suppl 1): S9-S15.
28. Allan DR, Penner SB, Smyth DD. Renal imidazoline preferring sites and solute excretion in the rat. Br J Pharmacol 1993; 108; 870-875.
29. Smyth DD, Penner SB. Renal I1-imidazoline receptor-selective compounds mediate natriuresis in the rat. J Cardiovasc Pharmacol 1995; 26 (Suppl 2): S63-S67.
30. 1-imidazoline preferring receptors: two unique sites mediating natriuresis in the rat. Br J Pharmacol 1994; 112: 1089-1994.
31. Wiecek A, Fliser D, Nowicki M, Ritz E. Effect of moxonidine on urinary electrolyte excretion and renal haemodynamics in man. Eur J Clin Pharmacol 1995; 48: 203-208.
32. Ernsberger P, Koletsky RJ, Collins LA, Bedol D. Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent. Cardiovasc Drug Ther 1996; 10 (Suppl 1): 275-282.
33. Weimann H-J, Rudolph M. Clinical pharmacokinetics of moxonidine. In: Schäfer SG, Christen MO, Ernsberger PR (eds). New Perspectives in the Treatment of Hypertension/The Imidazoline Receptor Agonist Moxonidine. Raven Press: New York, 1992, pp 69-77.
34. Theodor R, Weimann H-J, Weber W, Michaelis K. Absolute bioavailability of moxonidine. Eur J Drug Metab Pharmacokinet 1991; 16: 153-159.
35. Trenk D, Wagner F, Jähnchen E, Plänitz V. Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers. J Clin Pharmacol 1987; 27: 988-993.
36. Plänitz V, Hoffman K. First clinical data on moxonidine hydrochloride for treatment of mild to moderate hypertension. Nauyn Schmiedeberg Arch Pharmacol 1983; 342 (Suppl): R79.
37. Plänitz V. Treatment of hypertonia using various doses of moxonidine. Report on a moxonidine pilot study regarding the dosage interval. Kali-Chemie AG 1986: Report 220.5904.
38. Schwartz W, Kandziora J. Long-term experience with moxonidine, a new anti-hypertensive agent. Fortschr Med 1990; 108: 616-620.
39. Oldenbroek C. Double-blind, placebo-controlled, multicenter parallel group prospectively randomised study of the antihypertensive effects of moxonidine in patients with essential hypertension. Kali Chemi AG 1991: Report K.220.5004.
40. Eichstädt H et al. Demonstration of hypertrophy: regression with magnetic resonance tomography under the new adrenergic inhibitor moxonidine. Cardiovasc Drugs Ther 1989; 3 (Suppl 2): 583.
41. Kraft K, Vetter H. Twenty-four-hour blood pressure profiles in patients with mild-to-moderate hypertension: moxonidine versus captopril. J Cardiovasc Pharmacol 1994; 24 (Suppl 1): S29-S33.
42. Küppers HE et al. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens 1997; 15: 93-97.
43. Prichard BNC et al. A double-blind comparison of moxonidine and atenolol in the management of patients with mild-to-moderate hypertension. J Cordiovasc Pharmacol 1992; 20 (Suppl 4): S85-S93.
44. Wolf R. The treatment of hypertensive patients with a calcium antagonist or moxonidine. J Cardiovasc Pharmacol 1992; 20 (Suppl 4): S79-S84.
45. Frei M et al. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cordio Pharmacol 1994; 24 (Suppl 1): S25-S28.
46. Plänitz V. Intraindividual comparison of moxonidine and prazosin in hypertensive patients. Eur J Clin Pharmacol 1986; 29: 645-650.
47. Plänitz V. Crossover comparison of moxonidine and clonidine in mild to moderate hypertension. Eur J Clin Pharmacol 1984; 27: 147-152.
48. Plänitz V. Comparison of moxonidine clonidine HCl in treating patients with hypertension. J Clin Pharm 1987; 27(1): 46-51.
49. Macphee GJA, Howie CA, Elliott HL, Reid JL. A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects. Br J Clin Pharm 1992; 33: 261-267.
50. Rupp H, Maisch B, Brilla CG. Drug withdrawal and rebound hypertension: differential action of the central antihypertensive drugs moxonidine and clonidine. Cardiovasc Drug Ther 1996; 10: 251-262.
51. Webster J, Koch HF. Aspects of tolerability of centrally-acting antihypertensive drugs. J Cardiovasc Pharmacol 1996; 27 (Suppl 3): S49-S54.
52. Hamilton CA. Chemistry, mode of action and experimental pharmacology of moxonidine. In: van Zwieten PA, Hamilton CA, Jahu S, Prichard BNC (eds). The II imidazoline receptor agonist moxonidine: a new antihypertensive. 2nd Ed, Royal Society of Medicine Press Ltd: London, 1994, pp 1-41.
53. Schmidt U et al. Hypertension: a possible risk in road traffic. J Cardiovasc Pharmacol 1992; 20 (Suppl 4): S50-S56.
54. Mitrovic V et al. Haemodynamic effects of moxonidine in patients with congestive cardiac failure during the first three hours after administration of a single 0.4 mg dose [abstract]. 3rd Cardiovascular Pharmacology International Symposium, Kyoto 1989.
55. 2 adrenergic agonist, on histamine-induced bronchial constriction and ventilatory occlusion responses to carbon dioxide in asthmatics [abstract]. 3rd Cardiovascular Pharmacology International Symposium. Kyoto 1989.
56. 1-Imidazoline receptors: definition, characterization, distribution and transmembrane signalling. Annals New York Academy of Sciences 1995; 763: 22-42.
57. Regunathan S, Reis DJ. Imidazoline receptors and their endogenous ligands. Annu Rev Pharmacol Toxicol 1996; 36: 511-544.
58. van Zwieten PA. Central imidazoline receptors as a target for centrally acting antihypertensive drugs. Pharm World Sci 1995; 17(6): 186-190.